The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
about
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.Brain atrophy measurements should be used to guide therapy monitoring in MS - YES.Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry
P2860
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@ast
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@en
type
label
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@ast
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@en
prefLabel
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@ast
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@en
P2093
P2860
P1433
P1476
The Effect of Disease-Modifyin ...... ple Sclerosis: A Meta-Analysis
@en
P2093
Gilles Defer
Maria Pia Sormani
Pierre Branger
P2860
P304
P356
10.1371/JOURNAL.PONE.0149685
P407
P577
2016-03-16T00:00:00Z